Valuation: Savara Inc

Market Cap 127.58Cr 114.46Cr 105.83Cr 96Cr 179.06Cr 12TCr 181.22Cr 1.27TCr 503.97Cr 6.36TCr 478.75Cr 468.64Cr 20TCr P/E 2026 *
-8.31x
P/E 2027 * -12.9x
Enterprise Value 81Cr 73Cr 67Cr 61Cr 113.63Cr 7.71TCr 115.01Cr 802.95Cr 319.82Cr 4.03TCr 303.81Cr 297.4Cr 13TCr EV / Sales 2026 *
451x
EV / Sales 2027 * 11.9x
Free-Float
97.45%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 59 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 73 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%-3.36%+36.98%+60.50% 6.41TCr
+0.83%+2.53%+12.08%+83.63% 5.55TCr
+0.83%+1.11%+12.31%+103.92% 5.3TCr
+2.76%+0.87%+27.92%+55.07% 4.6TCr
+2.00%-3.39%+17.83%+119.04% 4.25TCr
+1.34%-2.86%+224.43%+914.08% 4.04TCr
+0.64%-3.95%+11.15%+45.57% 3.23TCr
-2.43%+42.65%+103.66%+90.16% 3.45TCr
-2.72%-0.44%+23.18%-10.77% 2.42TCr
Average +0.41%+4.08%+52.17%+162.36% 4.36TCr
Weighted average by Cap. +0.67%+3.49%+49.19%+160.27%

Financials

2026 *2027 *
Net sales 17.95L 16.11L 14.89L 13.49L 25.19L 17Cr 25.5L 1.78Cr 70.91L 8.95Cr 67.36L 65.94L 28Cr 7.96Cr 7.15Cr 6.61Cr 5.98Cr 11Cr 758.56Cr 11Cr 79Cr 31Cr 396.94Cr 30Cr 29Cr 1.26TCr
Net income -15Cr -14Cr -13Cr -11Cr -21Cr -1.44TCr -21Cr -149.61Cr -60Cr -751.8Cr -57Cr -55Cr -2.39TCr -9.41Cr -8.44Cr -7.81Cr -7.07Cr -13Cr -896.34Cr -13Cr -93Cr -37Cr -469.04Cr -35Cr -35Cr -1.49TCr
Net Debt -47Cr -42Cr -39Cr -35Cr -65Cr -4.44TCr -66Cr -462.33Cr -184.15Cr -2.32TCr -174.93Cr -171.24Cr -7.38TCr -33Cr -29Cr -27Cr -25Cr -46Cr -3.13TCr -47Cr -325.81Cr -129.77Cr -1.64TCr -123.28Cr -120.67Cr -5.2TCr
Logo Savara Inc
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Savara Inc